About this Research Topic
Parkinson’s disease (PD) is a growing global health challenge, affecting millions worldwide and imposing significant burdens on families and healthcare systems. This multifaceted neurodegenerative disorder is marked by progressive neuronal loss, leading to debilitating sensorimotor dysfunction and cognitive impairment. Early diagnosis and effective interventions remain critical yet unmet needs in PD care, as current therapeutic strategies often manage symptoms without halting disease progression.
Emerging advancements in biomedical research offer unprecedented opportunities to unravel the molecular, cellular, and neurophysiological mechanisms underlying PD, many of which remain elusive. By integrating artificial intelligence (AI) with innovations in genomics, proteomics, and metabolomics, researchers are revolutionizing our understanding of PD pathogenesis and unlocking new avenues for personalized and precision medicine. These approaches hold the promise of tailoring interventions to individual genetic, environmental, and lifestyle factors, significantly enhancing therapeutic outcomes.
Preclinical studies have paved the way for identifying genetic mutations and PD-specific biomarkers, offering pathways for early diagnosis and targeted therapies. In parallel, advancements in neuroimaging modalities such as MRI, PET, and EEG, alongside neuromodulation techniques like transcranial magnetic stimulation (TMS) and deep brain stimulation (DBS), are opening doors to personalized diagnostic and therapeutic solutions. AI and machine learning amplify these efforts, enabling predictive modeling to classify patient subtypes and forecast disease progression based on biomarker and neuroimaging data. These multidisciplinary approaches are critical for discovering novel therapeutic targets and optimizing treatment efficacy in personalized medicine for PD.
This Research Topic seeks to highlight the dynamic and transformative field of personalized medicine in PD, with a focus on diagnostic innovations and tailored treatment strategies. Contributors are invited to explore the following themes:
• Advancements in Biomarker Discovery: Novel insights into PD-specific biomarkers for early diagnosis and treatment stratification.
• Neuroimaging Innovations: Cutting-edge imaging techniques and their applications in personalized diagnosis and disease monitoring.
• AI and Machine Learning Applications: Predictive models for disease progression and patient-specific treatment responses.
• Personalized Therapeutic Strategies: Advances in pharmacogenomics, gene therapy, and neuromodulation approaches such as DBS.
• Role of Environmental and Lifestyle Factors: Influence on disease progression and integration into personalized treatment plans.
• Ethical and Psychosocial Considerations: Addressing the challenges and implications of personalized medicine in PD care.
This collection invites a wide range of contributions, including, but not limited to, original research, reviews, and case studies. Together, these works aim to deepen our understanding of personalized approaches to diagnosing and treating PD, advancing patient care and therapeutic success.
Emerging advancements in biomedical research offer unprecedented opportunities to unravel the molecular, cellular, and neurophysiological mechanisms underlying PD, many of which remain elusive. By integrating artificial intelligence (AI) with innovations in genomics, proteomics, and metabolomics, researchers are revolutionizing our understanding of PD pathogenesis and unlocking new avenues for personalized and precision medicine. These approaches hold the promise of tailoring interventions to individual genetic, environmental, and lifestyle factors, significantly enhancing therapeutic outcomes.
Preclinical studies have paved the way for identifying genetic mutations and PD-specific biomarkers, offering pathways for early diagnosis and targeted therapies. In parallel, advancements in neuroimaging modalities such as MRI, PET, and EEG, alongside neuromodulation techniques like transcranial magnetic stimulation (TMS) and deep brain stimulation (DBS), are opening doors to personalized diagnostic and therapeutic solutions. AI and machine learning amplify these efforts, enabling predictive modeling to classify patient subtypes and forecast disease progression based on biomarker and neuroimaging data. These multidisciplinary approaches are critical for discovering novel therapeutic targets and optimizing treatment efficacy in personalized medicine for PD.
This Research Topic seeks to highlight the dynamic and transformative field of personalized medicine in PD, with a focus on diagnostic innovations and tailored treatment strategies. Contributors are invited to explore the following themes:
• Advancements in Biomarker Discovery: Novel insights into PD-specific biomarkers for early diagnosis and treatment stratification.
• Neuroimaging Innovations: Cutting-edge imaging techniques and their applications in personalized diagnosis and disease monitoring.
• AI and Machine Learning Applications: Predictive models for disease progression and patient-specific treatment responses.
• Personalized Therapeutic Strategies: Advances in pharmacogenomics, gene therapy, and neuromodulation approaches such as DBS.
• Role of Environmental and Lifestyle Factors: Influence on disease progression and integration into personalized treatment plans.
• Ethical and Psychosocial Considerations: Addressing the challenges and implications of personalized medicine in PD care.
This collection invites a wide range of contributions, including, but not limited to, original research, reviews, and case studies. Together, these works aim to deepen our understanding of personalized approaches to diagnosing and treating PD, advancing patient care and therapeutic success.
Keywords: Neurodegenerative Diseases, Alzheimer's Diagnosis, Personalized Medicine, Precision Medicine, Genomic Biomarkers, Neuroimaging Techniques, AI in Healthcare, Multidisciplinary Research
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
